Anupama Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anupama Singh has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Charlotte N. Stahlfeld
University of Pittsburgh Medical Center Mercy Hospital Pittsburgh Pennsylvania USA
29 shared publications - Christos E. Kyriakopoulos
University of Wisconsin–Madison 17 Department of Medicine Madison, Wisconsin
29 shared publications - David J. Niles
Department of Biomedical Engineering, University of Wisconsin–Madison, Madison, Wisconsin
29 shared publications - Dawei Jiang
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
29 shared publications - Erika Heninger
University of Wisconsin–Madison 1 Madison, WI
29 shared publications - Howard R. Soule
13Department of Science, Prostate Cancer Foundation, Santa Monica, California
29 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S4. Biodistribution Study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S4. Biodistribution Study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S3. Scatter plot of gene expression for genes shown in Figure 3D isolated from matched anti-EPCAM vs anti-TROP-2 captured CTCs at the same timepoint.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S3. Scatter plot of gene expression for genes shown in Figure 3D isolated from matched anti-EPCAM vs anti-TROP-2 captured CTCs at the same timepoint.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S1. Correlation of TACSTD2 with Prostate Cancer Cell Surface Markers.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S1. Correlation of TACSTD2 with Prostate Cancer Cell Surface Markers.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S2. Capture Efficiency of TROP-2 Expressing Cell Lines.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S2. Capture Efficiency of TROP-2 Expressing Cell Lines.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S4. Biodistribution Study
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S4. Biodistribution Study
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S1. Correlation of TACSTD2 with Prostate Cancer Cell Surface Markers.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S1. Correlation of TACSTD2 with Prostate Cancer Cell Surface Markers.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S2. Capture Efficiency of Trop-2 Expressing Cell Lines.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S2. Capture Efficiency of Trop-2 Expressing Cell Lines.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S4. Biodistribution Study
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S4. Biodistribution Study
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S3. Scatter plot of gene expression for genes shown in Figure 3D isolated from matched anti-EpCAM vs anti-Trop2 captured CTCs at the same timepoint.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer
Figure S3. Scatter plot of gene expression for genes shown in Figure 3D isolated from matched anti-EpCAM vs anti-Trop2 captured CTCs at the same timepoint.